{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:29:03Z","timestamp":1786980543677,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10096-025-05293-4","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T10:38:07Z","timestamp":1759574287000},"page":"125-133","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring heterogeneity in antibiotic choices for bloodstream infections caused by AmpC-producing enterobacterales: results from a case-vignette study"],"prefix":"10.1007","volume":"45","author":[{"given":"Gianpiero","family":"Tebano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Campoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Meschiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Contadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Grasselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lazzaretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maritati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Raumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Scolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Vanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cristini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"key":"5293_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1128\/CMR.00036-08","volume":"22","author":"GA Jacoby","year":"2009","unstructured":"Jacoby GA (2009) AmpC \u03b2-lactamases. Clin Microbiol Rev 22:161\u2013182. https:\/\/doi.org\/10.1128\/CMR.00036-08","journal-title":"Clin Microbiol Rev"},{"key":"5293_CR2","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/cid\/ciz173","volume":"69","author":"PD Tamma","year":"2019","unstructured":"Tamma PD, Doi Y, Bonomo RA, Johnson JK, Simner PJ, Antibacterial Resistance Leadership Group (2019) A primer on AmpC \u03b2-lactamases: necessary knowledge for an increasingly multidrug-resistant world. Clin Infect Dis 69:1446\u20131455. https:\/\/doi.org\/10.1093\/cid\/ciz173","journal-title":"Clin Infect Dis"},{"key":"5293_CR3","doi-asserted-by":"publisher","first-page":"7753","DOI":"10.1128\/AAC.01729-15","volume":"59","author":"F Gu\u00e9rin","year":"2015","unstructured":"Gu\u00e9rin F, Isnard C, Cattoir V, Giard JC (2015) Complex regulation pathways of AmpC-mediated \u03b2-lactam resistance in Enterobacter cloacae complex. Antimicrob Agents Chemother 59:7753\u20137761. https:\/\/doi.org\/10.1128\/AAC.01729-15","journal-title":"Antimicrob Agents Chemother"},{"key":"5293_CR4","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1128\/JCM.43.6.2955-2958.2005","volume":"43","author":"K Kaneko","year":"2005","unstructured":"Kaneko K, Okamoto R, Nakano R, Kawakami S, Inoue M (2005) Gene mutations responsible for overexpression of AmpC beta-lactamase in some clinical isolates of Enterobacter cloacae. J Clin Microbiol 43:2955\u20132958. https:\/\/doi.org\/10.1128\/JCM.43.6.2955-2958.2005","journal-title":"J Clin Microbiol"},{"issue":"142","key":"5293_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/pharmacy12050142","volume":"12","author":"G Tebano","year":"2024","unstructured":"Tebano G, Zaghi I, Cricca M, Cristini F (2024) Antibiotic treatment of infections caused by AmpC-Producing enterobacterales. Pharm (Basel) 12(142):21. https:\/\/doi.org\/10.3390\/pharmacy12050142","journal-title":"Pharm (Basel)"},{"key":"5293_CR6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1128\/AAC.01083-07","volume":"52","author":"S-H Choi","year":"2008","unstructured":"Choi S-H, Lee JE, Park SJ, Choi S-H, Lee S-O, Jeong J-Y et al (2008) Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 52:995\u20131000. https:\/\/doi.org\/10.1128\/AAC.01083-07","journal-title":"Antimicrob Agents Chemother"},{"key":"5293_CR7","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1128\/AAC.45.9.2628-2630.2001","volume":"45","author":"KS Kaye","year":"2001","unstructured":"Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y (2001) Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 45:2628\u20132630. https:\/\/doi.org\/10.1128\/AAC.45.9.2628-2630.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"5293_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1093\/jac\/dkv346","volume":"71","author":"PNA Harris","year":"2016","unstructured":"Harris PNA, Wei JY, Shen AW, Abdile AA, Paynter S, Huxley RR et al (2016) Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother 71:296\u2013306. https:\/\/doi.org\/10.1093\/jac\/dkv346","journal-title":"J Antimicrob Chemother"},{"key":"5293_CR9","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ Infectious diseases society of America 2023 guidance on the treatment of antimicrobial resistant Gram-Negative infections. Clin Infect Dis 2023 18ciad428. https:\/\/doi.org\/10.1093\/cid\/ciad428","DOI":"10.1093\/cid\/ciad428"},{"key":"5293_CR10","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA Infectious diseases society of America 2024 guidance on the treatment of Antimicrobial-Resistant Gram-Negative infections. Clin Infect Dis 2024 7ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403","DOI":"10.1093\/cid\/ciae403"},{"key":"5293_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PAT.0000000000000255","volume":"47","author":"PNA Harris","year":"2015","unstructured":"Harris PNA, Alder L, Paterson DL (2015) Antimicrobial susceptibility reporting and treatment selection for AmpC-producing enterobacteriaceae: what do microbiologists and infectious disease practitioners actually practice? Pathology 47:386\u2013388. https:\/\/doi.org\/10.1097\/PAT.0000000000000255","journal-title":"Pathology"},{"key":"5293_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"1","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA et al (2022) European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 1:28:521\u2013547. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025","journal-title":"Clin Microbiol Infect"},{"key":"5293_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02447-y","author":"L Onorato","year":"2024","unstructured":"Onorato L, de Luca I, Salvati A, Monari C, Coppola N (2024) Piperacillin\/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis. Infection. https:\/\/doi.org\/10.1007\/s15010-024-02447-y","journal-title":"Infection"},{"key":"5293_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab387","volume":"8","author":"AG Stewart","year":"2021","unstructured":"Stewart AG, Paterson DL, Young B, Lye DC, Davis JS, Schneider K et al (2021) Meropenem versus Piperacillin-Tazobactam for definitive treatment of bloodstream infections caused by AmpC \u03b2-lactamase-producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: a pilot multicenter randomized controlled trial (MERINO-2). Open Forum Infect Dis 8:ofab387. https:\/\/doi.org\/10.1093\/ofid\/ofab387","journal-title":"Open Forum Infect Dis"},{"key":"5293_CR15","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1128\/AAC.01477-15","volume":"59","author":"N-Y Lee","year":"2015","unstructured":"Lee N-Y, Lee C-C, Li C-W, Li M-C, Chen P-L, Chang C-M et al (2015) Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by Cefepime-Susceptible Dose-Dependent isolates. Antimicrob Agents Chemother 59:7558\u20137563. https:\/\/doi.org\/10.1128\/AAC.01477-15","journal-title":"Antimicrob Agents Chemother"},{"key":"5293_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/cid\/cit395","volume":"57","author":"PD Tamma","year":"2013","unstructured":"Tamma PD, Girdwood SCT, Gopaul R, Tekle T, Roberts AA, Harris AD et al (2013) The use of cefepime for treating AmpC \u03b2-lactamase-producing Enterobacteriaceae. Clin Infect Dis 57:781\u2013788. https:\/\/doi.org\/10.1093\/cid\/cit395","journal-title":"Clin Infect Dis"},{"key":"5293_CR17","doi-asserted-by":"publisher","first-page":"e00276","DOI":"10.1128\/AAC.00276-17","volume":"61","author":"L Cheng","year":"2017","unstructured":"Cheng L, Nelson BC, Mehta M, Seval N, Park S, Giddins MJ et al (2017) Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC \u03b2-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother 61:e00276\u2013e00217. https:\/\/doi.org\/10.1128\/AAC.00276-17","journal-title":"Antimicrob Agents Chemother"},{"key":"5293_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106809","volume":"62","author":"A Maillard","year":"2023","unstructured":"Maillard A, Delory T, Bernier J, Villa A, Chaibi K, Escaut L et al (2023) Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC \u03b2-lactamase-producing enterobacterales: a multi-centre retrospective propensity-weighted study. Int J Antimicrob Agents 62:106809. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106809","journal-title":"Int J Antimicrob Agents"},{"key":"5293_CR19","doi-asserted-by":"publisher","unstructured":"Hardy ME, Kenney RM, Tibbetts RJ, Shallal AB, Veve MP Leveraging stewardship to promote ceftriaxone use in severe infections with low- and no-risk AmpC enterobacterales. Antimicrob Agents Chemother 2023 15;67:e0082623. https:\/\/doi.org\/10.1128\/aac.00826-23","DOI":"10.1128\/aac.00826-23"},{"key":"5293_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107186","volume":"28","author":"M Meschiari","year":"2024","unstructured":"Meschiari M, Asquier-Khati A, Tiseo G, Luque-Paz D, Murri R, Boutoille D et al (2024) Treatment of infections caused by multi-drug-resistant Gram-negative bacilli: a practical approach by the Italian (SIMIT) and French (SPILF) societies of infectious diseases. Int J Antimicrob Agents 28:107186. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107186","journal-title":"Int J Antimicrob Agents"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05293-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05293-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05293-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T13:19:53Z","timestamp":1770211193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05293-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5293"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05293-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. According to legislation, ethical approval was not required, since no patient was involved and no real clinical data were included. All participants were senior physicians and participation was voluntary and not remunerated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}